Hylomorph Medical raises €5.5M Series B round
3 December 2021· Zurich, Switzerland· health, medical_devices, biomaterials, biotech, b2b, deep_hardware
The funding aims at safely bringing the company to FDA and CE mark approval of its product portfolio, beginning with the blockbuster Hylomate®.
Investors
LeadGeneva Smart Invest
Also participating
Zürcher KantonalbankEFI Lake Geneva VenturesStart Angels NetworkVerve Ventures
About Hylomorph Medical
Stage
Series B
Headquarters
Zurich, Switzerland
Founded
2014
Team Size
6–20
Sectors
healthmedical_devicesbiomaterialsbiotechb2bdeep_hardware